デフォルト表紙
市場調査レポート
商品コード
1405886

POC(ポイントオブケア)分子診断市場規模、シェア、動向分析レポート:用途別、技術別、検査拠点別、最終用途別、地域別、セグメント予測、2024年~2030年

Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
POC(ポイントオブケア)分子診断市場規模、シェア、動向分析レポート:用途別、技術別、検査拠点別、最終用途別、地域別、セグメント予測、2024年~2030年
出版日: 2023年12月21日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

POC(ポイントオブケア)分子診断市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界のPOC(ポイントオブケア)分子診断市場規模は、2024年から2030年にかけてCAGR 2.5%を記録し、2030年には101億2,000万米ドルに達すると予測されています。

COVID-19、HIV、HBC、HCVのような感染症の有病率の上昇と老年人口の増加が、POC分子診断検査の必要性を煽ると予測されています。さらに、これらのPOC検査が提供する迅速で正確な結果は、地域全体で受け入れが拡大している主な要因となっています。さらに、新興国では在宅医療や介護施設の重要性が高まっていることも、予測期間中のPOC分子診断市場の成長を後押しすると予測されます。

世界の老年人口は増加しており、POC分子診断の需要を押し上げると予想されます。WHOが発表した推計によると、世界の65歳以上の人口は2000年の7%から2050年には16%に増加する見込みです。高齢化は心血管疾患やがんなどの疾病リスクを高める。したがって、世界の老人人口の増加は、在宅ヘルスケアや生活支援ヘルスケア施設など、POC MDxを必要とする施設を通じた継続的モニタリングの需要を高めると予想されます。日本と中国は最も影響を受けるアジア諸国の一つであり、日本の老人人口の大幅な増加が予想されます。現在、日本の人口の20%以上が65歳以上です。

各国におけるがんの有病率の増加は、病院内でのPOC(ポイントオブケア)分子診断検査に対する継続的な需要をもたらしています。National Center for Chronic Disease Prevention and Health Promotionによると、年間がん罹患者数は2015年の153万人から2050年には228万人に増加する見込みです。さらに、がん検出のためのCRISPRとNGS技術の出現は、診断率を飛躍的に向上させました。また、過去10年間でNGSの価格が手頃になったことも、がん領域のPOC分子診断市場に利益をもたらしています。このような要因が世界市場を牽引する可能性が高いです。

POC分子診断市場に参入している主な企業には、ダナハー、バイオメリュー、バイオ・ラッド・ラボラトリーズ、アボット、F.ホフマン・ラ・ロシュ、BDなどがあります。多くのパイロットプログラムが開始され、市場に新製品が登場する可能性が高いです。例えば、2022年3月、Intermountain Healthcareは、50人の従業員を対象にGalleri Multi-Cancer Early Detection Testをパイロットプランとして展開すると発表しました。

POC(ポイントオブケア)分子診断市場レポートハイライト

  • 技術別では、COVID-19やその他の感染症診断のためのRT-PCR検査の需要増加により、PCRベースのセグメントがPOC(ポイントオブケア)分子診断市場で大きなシェアを占めています。
  • 病院、診療所、外来センターが迅速なPOC検査を選択する需要が増加しているため、POC検査場所セグメントは予測期間中に大きく成長する見込みです。
  • 2023年の世界市場は北米が支配的であったが、これは新技術に対する需要の増加、主要プレイヤーの大規模なプール、がんや感染症の有病率の上昇、先進的なヘルスケアインフラに起因します。
  • アジア太平洋地域は、医療インフラが整備され、がん検査に対する認識が高まっているため、今後大きく成長すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因
  • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析;要因別(政治・法律、経済・技術)
    • ポーターのファイブフォース分析
    • COVID-19感染症の影響分析

第4章 技術のビジネス分析

  • POC(ポイントオブケア)分子診断市場:技術変動分析
  • PCRベース
  • 遺伝子配列ベース
  • ハイブリダイゼーションベース
  • マイクロアレイベース

第5章 用途のビジネス分析

  • POC(ポイントオブケア)分子診断市場:用途の変動分析
  • 感染症
    • HIV POC
    • クロストリジウム・ディフィシルPOC
    • HBV POC
    • 肺炎または連鎖球菌関連感染症
    • 呼吸器合胞体ウイルス(RSV)POC
    • HPV POC
    • インフルエンザ/インフルエンザ POC
    • HCV POC
    • MRSA POC
    • 結核と薬剤耐性結核のPOC
    • HSV POC
    • その他の感染症
  • 腫瘍学
  • 血液学
  • 出生前検査
  • 内分泌学
  • その他

第6章 検査拠点のビジネス分析

  • POC(ポイントオブケア)分子診断市場:検査拠点の変動分析
  • OTC
  • POC

第7章 最終用途のビジネス分析

  • POC(ポイントオブケア)分子診断市場:最終用途変動分析
  • 分散型ラボ
  • 病院
  • 在宅ケア
  • 生活支援ヘルスケア施設
  • その他

第8章 地域のビジネス分析

  • 地域別POC(ポイントオブケア)分子診断市場シェア、2023年および2030年
  • 北米
    • 北米のPOC(ポイントオブケア)分子診断市場、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州のPOC(ポイントオブケア)分子診断市場、2018年から2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋POC(ポイントオブケア)分子診断市場、2018年から2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカのPOC(ポイントオブケア)分子診断市場、2018年から2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEAPOC(ポイントオブケア)分子診断市場、2018~2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • POC(ポイントオブケア)分子診断市場シェア分析、2023年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • TABLE 1 Point-of-care Molecular Diagnostics market - Industry Snapshot & Key Buying Criteria, 2018 - 2030
  • TABLE 2 Global Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 3 Global Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 4 Global Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 5 Global Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 6 Global Point-of-care Molecular Diagnostics market, by region, 2018 - 2030 (USD Million)
  • TABLE 7 Point-of-care Molecular Diagnostics- Key market driver analysis
  • TABLE 8 Point-of-care Molecular Diagnostics- Key market restraint analysis
  • TABLE 9 North America Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 10 North America Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 11 North America Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 12 North America Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 13 North America Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 14 US Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 15 US Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 16 US Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 17 US Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 18 Canada Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 19 Canada Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 20 Canada Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 21 Canada Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 22 Europe Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 23 Europe Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 24 Europe Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 25 Europe Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 26 Europe Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 27 Germany Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 28 Germany Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 29 Germany Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 30 Germany Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 31 UK Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 32 UK Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 33 UK Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 34 UK Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 35 France Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 36 France Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 37 France Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 38 France Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 39 Italy Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 40 Italy Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 41 Italy Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 42 Italy Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 43 Spain Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 44 Spain Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 45 Spain Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 46 Spain Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 47 Denmark Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 48 Denmark Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 49 Denmark Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 50 Denmark Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 51 Sweden Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 52 Sweden Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 53 Sweden Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 54 Sweden Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 55 Norway Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 56 Norway Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 57 Norway Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 58 Norway Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 59 Asia Pacific Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 60 Asia Pacific Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 61 Asia Pacific Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 62 Asia Pacific Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 63 Asia Pacific Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 64 Japan Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 65 Japan Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 66 Japan Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 67 Japan Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 68 China Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 69 China Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 70 China Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 71 China Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 72 India Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 73 India Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 74 India Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 75 India Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 76 Australia Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 77 Australia Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 78 Australia Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 79 Australia Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 80 South Korea Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 81 South Korea Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 82 South Korea Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 83 South Korea Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 84 Thailand Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 85 Thailand Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 86 Thailand Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 87 Thailand Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 88 Latin America Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 89 Latin America Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 90 Latin America Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 91 Latin America Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 92 Latin America Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 93 Brazil Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 94 Brazil Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 95 Brazil Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 96 Brazil Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 97 Mexico Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 98 Mexico Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 99 Mexico Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 100 Mexico Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 101 Argentina Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 102 Argentina Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 103 Argentina Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 104 Argentina Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 105 MEA Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 106 MEA Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 107 MEA Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 108 MEA Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 109 MEA Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 110 South Africa Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 111 South Africa Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 112 South Africa Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 113 South Africa Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 114 Saudi Arabia Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 115 Saudi Arabia Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 116 Saudi Arabia Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 117 Saudi Arabia Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 118 UAE Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 119 UAE Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 120 UAE Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 121 UAE Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 122 Kuwait Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 123 Kuwait Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 124 Kuwait Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 125 Kuwait Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Point-of-care Molecular Diagnostics Market Segmentation
  • FIG. 2 Global Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 3 Point-of-care Molecular Diagnostics Market Dynamics
  • FIG. 4 Key opportunities prioritized, 2018
  • FIG. 5 Point-of-care Molecular Diagnostics Market - Porter's Analysis
  • FIG. 6 Point-of-care Molecular Diagnostics Market - PESTEL analysis
  • FIG. 7 Point-of-care Molecular Diagnostics revenue share, by application, 2023 & 2030
  • FIG. 8 POC MDx Infectious Diseases Market, 2018 - 2030 (USD Million)
  • FIG. 9 POC MDx Oncology Market, 2018 - 2030 (USD Million)
  • FIG. 10 POC MDx Hematology Market, 2018 - 2030 (USD Million)
  • FIG. 11 POC MDx Prenatal Testing Market, 2018 - 2030 (USD Million)
  • FIG. 12 POC MDx Endocrinology Market, 2018 - 2030 (USD Million)
  • FIG. 13 POC MDx Other Applications Market, 2018 - 2030 (USD Million)
  • FIG. 14 Point-of-care Molecular Diagnostics revenue share, by technology, 2023 & 2030
  • FIG. 15 POC MDx PCR-based Market, 2018 - 2030 (USD Million)
  • FIG. 16 POC MDx Genetic Sequencing-based Market, 2018 - 2030 (USD Million)
  • FIG. 17 POC MDx Hybridization-based Market, 2018 - 2030 (USD Million)
  • FIG. 18 POC MDx Microarray-based Market, 2018 - 2030 (USD Million)
  • FIG. 19 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
  • FIG. 20 POC MDx over-the-counter Market, 2018 - 2030 (USD Million)
  • FIG. 21 POC MDx point-of-care Market, 2018 - 2030 (USD Million)
  • FIG. 22 Point-of-care Molecular Diagnostics revenue share, by End-use, 2023 & 2030
  • FIG. 23 POC MDx Decentralized Labs Market, 2018 - 2030 (USD Million)
  • FIG. 24 POC MDx Hospitals Market, 2018 - 2030 (USD Million)
  • FIG. 25 POC MDx Home-care Market, 2018 - 2030 (USD Million)
  • FIG. 26 POC MDx Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)
  • FIG. 27 POC MDx Other uses Market, 2018 - 2030 (USD Million)
  • FIG. 28 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
  • FIG. 29 POC MDx OTC Market, 2018 - 2030 (USD Million)
  • FIG. 30 POC MDx POC Market, 2018 - 2030 (USD Million)
  • FIG. 31 Point-of-care Molecular Diagnostics revenue share, by region, 2023 & 2030
  • FIG. 32 North America Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 33 US Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 34 Canada Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 35 Europe Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 36 Germany Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 37 UK Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 38 France Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 39 Italy Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 40 Spain Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 41 Denmark Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 42 Sweden Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 43 Norway Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 44 Asia Pacific Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 45 Japan Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 46 China Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 47 India Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 48 Australia Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 49 South Korea Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 50 Thailand Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 51 Latin America Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 52 Brazil Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 53 Mexico Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 54 Argentina Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 55 MEA Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 56 South Africa Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 57 Saudi Arabia Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 58 UAE Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 59 Kuwait Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
目次
Product Code: 978-1-68038-886-2

Point-of-Care Molecular Diagnostics Market Growth & Trends:

The global point-of-care molecular diagnostics market size is expected to reach USD 10.12 billion by 2030, registering a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as COVID-19, HIV, HBC, HCV, along with growing geriatric population is predicted to fuel the need for POC molecular diagnostics tests. Furthermore, rapid and accurate results offered by these POC tests act as a major factor for such growing acceptance across geographies. Moreover, rising emphasis for home care and assisted care facilities across emerging economies is also predicted boost POC molecular diagnostics market growth during the forecast years.

Global geriatric population is increasing, which is expected to boost the demand for POC molecular diagnostics. Estimates published by the WHO suggest that the global population of age group 65 years and above is expected to increase from 7% in 2000 to 16% in 2050. Aging elevates the risk of diseases such as cardiovascular and cancer. Therefore, increase in global geriatric population is expected to raise the demand for continuous monitoring via facilities requiring POC MDx, such as home healthcare and assisted living healthcare facilities. Japan and China are two of the most affected Asian countries, and a significant increase in Japan's geriatric population is anticipated. Currently, more than 20% of the country's population is over the age of 65 years.

Increasing prevalence of cancer across countries has resulted in a continuous demand for point-of-care molecular diagnostic tests within hospitals. According to the National Center for Chronic Disease Prevention and Health Promotion, the annual cancer cases are likely to grow from 1.53 million in 2015 to 2.28 million by 2050. CDC has predicted incidence is likely to increase by 50% owing to increasing population within the U.S. Furthermore, emergence of CRISPR and NGS techniques for cancer detection has improved the diagnosis rates tremendously. With increasing affordability of NGS in past decade has also benefited the POC molecular diagnostics market for oncology. Such factors are likely to drive the global market.

Major companies active in the POC molecular diagnostics market include Danaher, BioMerieux, Bio-Rad Laboratories, Inc., Abbott, F. Hoffmann-La Roche AG, BD, and many more. Large number of pilot programs being initiated are likely to bring new products in the market. For instance, in march 2022, Intermountain Healthcare announced that they will be rolling out a Galleri Multi-Cancer Early Detection Test for 50 of their employees as a pilot plan, with this the company is expecting to launch new product in order to improve their market position.

Point-of-Care Molecular Diagnostics Market Report Highlights:

  • By technology, the PCR-based segment held a larger share of the point-of-care molecular diagnostics market owing to increasing demand for RT-PCR tests for diagnosis of COVID-19 and other infectious diseases
  • The POC test location segment is expected to grow lucratively over the forecast period due to rising demand from hospitals, clinics and ambulatory centers opting for rapid POC tests
  • North America dominated the global market in 2023, owing to increasing demand for new technologies, a large pool of key players, rising prevalence of cancer, infectious diseases, and advanced healthcare infrastructure
  • The Asia Pacific is expected to grow considerably in the future owing to due to the growing healthcare infrastructure and rising awareness of cancer testing within the region

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
  • 3.5. Market Restraint Analysis
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based Market, 2018 - 2030 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based Market, 2018 - 2030 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based Market, 2018 - 2030 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC Market, 2018 - 2030 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC Market, 2018 - 2030 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC Market, 2018 - 2030 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2018 - 2030 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2018 - 2030 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC Market, 2018 - 2030 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC Market, 2018 - 2030 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC Market, 2018 - 2030 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC Market, 2018 - 2030 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC Market, 2018 - 2030 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC Market, 2018 - 2030 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology Market, 2018 - 2030 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing Market, 2018 - 2030 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC Market, 2018 - 2030 (USD Million)
  • 6.3. POC
    • 6.3.1. POC Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End-Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs Market, 2018 - 2030 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.4. Home-care
    • 7.4.1. Home-care Market, 2018 - 2030 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2023 & 2030
  • 8.2. North America
    • 8.2.1. North America Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Mexico Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Argentina Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Point-of-Care Molecular Diagnostics market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Abbott
      • 9.3.3.1.1. Company Overview
      • 9.3.3.1.2. Financial Performance
      • 9.3.3.1.3. Product Benchmarking
      • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Bayer AG
      • 9.3.3.2.1. Company Overview
      • 9.3.3.2.2. Financial Performance
      • 9.3.3.2.3. Product Benchmarking
      • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. F. Hoffmann-La Roche AG
      • 9.3.3.3.1. Company Overview
      • 9.3.3.3.2. Financial Performance
      • 9.3.3.3.3. Product Benchmarking
      • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Nova Biomedical
      • 9.3.3.4.1. Company Overview
      • 9.3.3.4.2. Financial Performance
      • 9.3.3.4.3. Product Benchmarking
      • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. QIAGEN
      • 9.3.3.5.1. Company Overview
      • 9.3.3.5.2. Financial Performance
      • 9.3.3.5.3. Product Benchmarking
      • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Nipro Diagnostics
      • 9.3.3.6.1. Company Overview
      • 9.3.3.6.2. Financial Performance
      • 9.3.3.6.3. Product Benchmarking
      • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Danaher
      • 9.3.3.7.1. Company Overview
      • 9.3.3.7.2. Financial Performance
      • 9.3.3.7.3. Product Benchmarking
      • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Bio-Rad Laboratories, Inc.
      • 9.3.3.8.1. Company Overview
      • 9.3.3.8.2. Financial Performance
      • 9.3.3.8.3. Product Benchmarking
      • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. bioMerieux
      • 9.3.3.9.1. Company Overview
      • 9.3.3.9.2. Financial Performance
      • 9.3.3.9.3. Product Benchmarking
      • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Agilent Technologies, Inc.
      • 9.3.3.10.1. Company Overview
      • 9.3.3.10.2. Financial Performance
      • 9.3.3.10.3. Product Benchmarking
      • 9.3.3.10.4. Strategic Initiatives
      • 9.3.3.11. Abaxis
      • 9.3.3.11.1. Company Overview
      • 9.3.3.11.2. Financial Performance
      • 9.3.3.11.3. Product Benchmarking
      • 9.3.3.11.4. Strategic Initiatives
      • 9.3.3.12. OraSure Technologies
      • 9.3.3.12.1. Company Overview
      • 9.3.3.12.2. Financial Performance
      • 9.3.3.12.3. Product Benchmarking
      • 9.3.3.12.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others